GlobalData

Breast cancer treatment
#Antibody drug conjugate (ADC) #Breast cancer #Cancer research #FDA #Gilead Sciences #GlobalData #Oncology

ADC potential “standard of care” for some breast cancer patients

The FDA has granted expanded approval for Gilead Sciences’ Trodelvy (sacituzumab govitecan-hziy) for patients with HR-positive/HER2-negative metastatic breast cancer who have received hormonal therapy and at least two additional therapies in the metastatic setting.  The drug is expected to become a standard of care for these patients,… Read More

#News #Trending News

#Biopharmaceuticals #GlobalData #Market reporting #Pharmaceutical industry

Top 20 global biopharma companies report 5.4% growth

The top 20 biopharmaceutical companies have recorded a growth of 5.4% in aggregate market capitalisation – from $3.43 trillion on December 31, 2021 to $3.61 trillion on December 31, 2022.  According to analytics company GlobalData, 11 companies indicated double-digit growth, with four companies – Merck & Co (45.3%), Vertex Pharmaceuticals… Read More

#Business & Investment #Editor's Choice #Market Reports #News

Live disease
#FDA #Fibrosis #GlobalData #Intercept Pharmaceuticals #Liver disease #Regulatory #Trial data #United States

First drug for NASH under second FDA review

Intercept Pharmaceuticals’ obeticholic acid (OCA) could be first drug to be approved in the US for non-alcoholic steatohepatitis (NASH), according to analysts GlobalData.  The Food and Drug Administration (FDA) accepted the company’s resubmission of its new drug application (NDA) for OCA in patients with pre-cirrhotic liver fibrosis due to NASH… Read More

#News #Regulatory

Lecanemab
#Alzheimer's #Biogen #Eisai #FDA #GlobalData #Monoclonal antibodies #United States

Uncertainty surrounds monoclonal antibody for Alzheimer’s

Leqembi’s prospects in the Alzheimer’s disease market remain uncertain despite its advantages over Aduhelm, says analytics company GlobalData.  Eisai and Biogen’s anti-amyloid beta (Aβ) monoclonal antibody (mAb), Leqembi (lecanemab), recently gained approval from the Food and Drug Administration (FDA) under the accelerated approval pathway for the treatment of Alzheimer’s disease… Read More

#News #Regulatory

#Covid-19 #GlobalData #Manufacturing

Opportunities linked to increase in FDA approvals of Covid-19 products  

An increasing number of approvals and Emergency Use Authorisations (EUAs) by the Food and Drug Administration (FDA) for Covid-19 vaccines and drugs, as well as cell and gene therapies, is helping provide manufacturing opportunities for contract manufacturing organisations (CMOs).  This is according to GlobalData’s latest report –… Read More

#News

Sickle cells
#GlobalData #Sickle cells #Therapeutics

How US sickle cell disease market will reach $4.8 billion by 2030 

A number of new sickle cell disease (SCD) drugs are set to hit the US market, says GlobalData, including gene therapies that could offer patients a cure.   The cause of the increase  GlobalData notes that one of the gene therapies that is currently closest to… Read More

#News

#CAR-T #GlobalData #Immunotherapy

Analysts expect competition in CAR-T therapies in Japan 

Janssen Pharmaceutical has recently filed for B-cell maturation antigen (BCMA) CAR-T therapy Cilta-cel in Japan. Earlier in March 2021, Bristol-Myers Squibb (BMS) filed for the first BCMA CAR-T therapy idecabtagene vicleucel, in the country. Following approval by the Japanese regulatory authority, BMS will have the first-mover advantage. However, stiff competition is expected… Read More

#News #Trending News

#Drug development #Drug discovery #GlobalData #siRNA #Therapeutics

Chinese pharma companies eye strategic alliances for therapeutics

The overall potential of siRNA-based therapeutics has attracted Chinese pharma companies to tap opportunities and bring promising innovative therapies across the globe, according to reporting by GlobalData. Against this backdrop, the Chinese pharma companies have increased their focus towards the siRNA pipeline through strategic alliances.  China pharma… Read More

#News #Trending News

#Clinical trials #Covid-19 #GlobalData

UK falls behind other countries in clinical trial activity 

While trial activity has since recovered to pre-Covid-19 pandemic levels in Australia and the US, the UK remains behind, according to reporting by Andrew Hillman, healthcare and pharmaceuticals data journalist at GlobalData.  Hillman explained that the UK commenced 18% fewer commercial trials during the first three quarters of 2021 than… Read More

#Covid-19 #News #Trending News

#Digital therapeutics #GlobalData #Pharmaceuticals #Therapeutics

Opportunities in Japan’s neurology digital therapeutics market

Digital therapeutics (DTx) uses digital technology to remotely prevent, treat, or manage a wide range of conditions through data-driven interventions; GlobalData says several opportunities exist in the digital therapeutics market for neurological diseases in Japan.  Shionogi & Co, a partner of Akili Interactive, a prescription digital medicine company of PureTech Health, has… Read More

#News #Trends & Analysis

#Biopharmaceuticals #Covid-19 #GlobalData

Covid-19 shapes Indian pharma deals landscape

India has a rapidly growing pharmaceutical market that, being the third largest pharmaceutical industry in the world by volume, holds a prominent place in global health. Over the last decade, the Indian pharmaceutical market has seen increasing domestic and foreign investment. While the overall number of deals fluctuated only slightly… Read More

#Covid-19 #News #Trends & Analysis

#Covid-19 #GlobalData #Immunology / Virology & Vaccines #mRNA

Too many US adults unvaccinated to vaccinate children 

Following the news that Pfizer/BioNTech will apply for authorisation of their Covid-19 vaccine Comirnaty for children ages 5–11 after showing positive initial data from a trial at a lower dose in this age group; Philipp Rosenbaum, Senior Healthcare Analyst at GlobalData, offers his view.   He said: “It will be… Read More

#Covid-19 #News #Trends & Analysis

#Drug development #Drug discovery #GlobalData #Novel therapeutics

PD market to reach $1.95 billion in 2030 driven by novel therapies

An upcoming influx of new therapies into the Pompe disease (PD) pipeline in the next decade is expected by GlobalData to provide a significant boost to the treatment market for this inherited, and often fatal, disorder that can greatly damage the heart and skeletal muscles. In fact, the market is expected to… Read More

#News #Trends & Analysis

#CAR-T #Cell therapy #GlobalData #Oncology #Tumour biology

Off-the-shelf potential for NK cell therapies for tumour treatment 

Natural killer (NK) cell therapies have the potential to be an effective, off-the-shelf treatment for a range of cancers. Analysis of NK cell therapies, currently in development, reveals that 57% of these are allogeneic therapies, and although development in haematological indications is more advanced, there are a high number of therapies… Read More

#Cancer Research #News